Electroacupuncture produces analgesic effects via cannabinoid CB1 receptor-mediated GABAergic neuronal inhibition in the rostral ventromedial medulla.

Researchers have discovered how electroacupuncture relieves pain by studying its effects on specific brain cells in mice. Electroacupuncture is a form of acupuncture where mild electrical currents are applied through the needles to enhance the treatment's effectiveness.

The study examined two types of pain: inflammatory pain (similar to arthritis) and nerve pain. Scientists applied electroacupuncture to the "Zusanli" point (ST36), a commonly used acupuncture point on the leg. They used advanced imaging techniques to watch brain cell activity in real time and tested various ways to turn specific neurons on or off.

The results showed that electroacupuncture significantly reduced pain in both types of pain conditions. The researchers found that pain increased the activity of certain inhibitory neurons in a brain region called the rostral ventromedial medulla, which plays an important role in pain control. Electroacupuncture worked by calming down these overactive neurons through cannabinoid CB1 receptors—the same receptors that respond to the body's natural pain-relieving chemicals.

When researchers blocked these CB1 receptors or artificially activated the pain-promoting neurons, electroacupuncture could no longer provide pain relief. This confirms that this specific brain pathway is essential for electroacupuncture's pain-relieving effects.

For patients, this research helps explain why electroacupuncture can be effective for both inflammatory conditions and nerve pain. It provides scientific evidence supporting electroacupuncture as a treatment option for chronic pain management. If you're considering electroacupuncture for pain relief, consult with a licensed acupuncturist who has specific training in electroacupuncture techniques.

This study elucidates the neurobiological mechanisms of electroacupuncture analgesia using CFA-induced inflammatory and CCI-induced neuropathic pain models in mice. Researchers employed in vivo calcium imaging, electrophysiology, in situ hybridization, and chemogenetics to assess GABAergic neuronal activity in the rostral ventromedial medulla (RVM).

EA at ST36 ipsilateral to injury produced significant analgesic effects in both pain models. Both CFA and CCI elevated calcium activity in GABARVM neurons, which inhibit descending pain-modulating off-cells. EA treatment decreased calcium activity, firing rates, and c-Fos expression in these neurons. Chemogenetic inhibition of GABARVM neurons increased nociceptive thresholds, while activation induced hyperalgesia and blocked EA analgesia.

Critically, reducing cannabinoid CB1 receptor expression on GABARVM neurons eliminated EA's analgesic effects. Clinical takeaway: EA produces analgesia in both inflammatory and neuropathic pain through CB1 receptor-mediated inhibition of GABAergic neurons in the RVM, providing mechanistic support for EA in treating diverse chronic pain conditions. Ipsilateral needling may optimize descending pain modulation.